logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Expanding access to lifesaving new TB tools | Collections | MSF Science Portal

Many settings with a high burden of drug-resistant tuberculosis (DR-TB) lack access to advanced diagnostics and to groundbreaking new treatments. The Collection linked below spotlights work by MSF and collaborators to analyze barriers, identify gaps, and accelerate the roll-out of these tools to people whose lives hang in the balance.

Several reports examine price, regulatory, and patent obstacles that persist despite considerable public investment into developing many of these tools. Other authors examine critical remaining weaknesses in care pathways—especially in screening and diagnosis, and particularly in children. Several studies describe new strategies that could be part of the solution, from a pilot program in Tajikisttan that trains family caregivers to treat children with DR-TB at home, to a person-centered care model adapted to a conflict zone in Afghanistan. Lastly, initial findings demonstrate that pregnant women—another vulnerable population—can be effectively treated for DR- and multidrug-resistant TB, improving maternal outcomes without harming neonates.

Collection Content

Journal Article
|
Short Report

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y,  et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...
Journal Article
|
Research

Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq

Tesfahun HM, Al-Salihi L, Abdulkareem Al-Ani N, Mankhi AA, Mohammed A,  et al.
2024-01-19 • PLOS One
2024-01-19 • PLOS One
Since December 2019, the World Health Organization (WHO) has encouraged National Tuberculosis Programs to deprioritize the use of injectable-containing regimens and roll-out all-oral bed...
Journal Article
|
Commentary

Reversing the neglect of children and adolescents affected by tuberculosis

Deborggraeve S, Casenghi M, Hewison CCH, Ditekemena J, Ditiu L,  et al.
2023-09-11 • Lancet Child and Adolescent Health
2023-09-11 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Diagnostics to support the scaling up of shorter, safer tuberculosis regimens

Branigan D, Denkinger CM, Furin J, Heitkamp P, Deborggraeve S,  et al.
2023-07-31 • Lancet Microbe
2023-07-31 • Lancet Microbe
Technical Report
|
Policy Brief

DR-TB drugs under the microscope 2022

MSF Access Campaign
2022-11-08
2022-11-08
TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to ...
Journal Article
|
Letter

Family directly observed therapy for children with drug-resistant TB

Rekart ML, Morshed T, Mulanda WK, Klieascikova J, Sitali N,  et al.
2022-08-01 • International Journal of Tuberculosis and Lung Disease
2022-08-01 • International Journal of Tuberculosis and Lung Disease
Journal Blog
|
Perspective

6 months TB treatment for (almost) all

Berry C
2022-05-10 • PLoS Blogs
2022-05-10 • PLoS Blogs
Journal Article
|
Commentary

Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

Perrin C, Athersuch K, Elder G, Martin M, Alsalhani A
2022-04-19 • BMJ Global Health
2022-04-19 • BMJ Global Health
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently ...
Journal Article
|
Research

Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan

Mesic A, Ishaq S, Khan WH, Mureed A, Mar HT,  et al.
2022-01-03 • Tropical Medicine and International Health
2022-01-03 • Tropical Medicine and International Health
OBJECTIVES
To describe the effect of adaptations to a person-centred care with short oral regimens on retention in care for rifampicin-resistant TB (RR-TB) in Kandahar province, Afgh...
Journal Article
|
Research

Public investments in the development of GeneXpert molecular diagnostic technology

Gotham D, McKenna L, Deborggraeve S, Madoori S, Branigan D
2021-08-31 • PLOS One
2021-08-31 • PLOS One
BACKGROUND
The GeneXpert diagnostic platform from the US based company Cepheid is an automated molecular diagnostic device that performs sample preparation and pathogen detection wit...

See more collections

MSF logo

International Women's Day 2023
No description available
MSF Paediatric Days 2024 abstracts

MSF Paediatric Days 2024 abstracts
On 3-4 May in Nairobi, Kenya, MSF gathered staff from our projects with experts from academia, clinical practice and the non-governmental sector to consider key issues in humanitarian paediatrics. These included: Vaccination and vaccine-preventable diseases: Amid post-Covid-19 global setbacks in child vaccination coverage, sessions spotlighted recent increases in vaccine-preventable disease outbreaks, potential new vaccination strategies and emergency responses, and MSF’s role in vaccine advocacy and catch-up campaigns. Nutrition: Talks covered the nexus of nutrition with other key conference topics, the latest malnutrition guidance and tools, and MSF’s priorities in nutritional care. Paediatric HIV: With half of all HIV-positive children globally not receiving antiretroviral therapy, presenters reviewed the latest paediatric testing/treatment recommendations and discussed barriers and potential solutions to implementation, nutritional challenges in children with HIV, and systems strengthening for preventing and monitoring paediatric HIV. Click below to read the abstracts. And stay tuned for more conference content, coming soon.
Diabetes in humanitarian settings 2022

Diabetes in humanitarian settings 2022
No description available
View All Collections
Expanding access to lifesaving new TB tools

Expanding access to lifesaving new TB tools